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Abstract 
Background: The World Health Organization recommends the provision of intermittent preventive treatment during 
pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) at 4-week intervals from gestational week 13 to delivery in 
areas of moderate to high malaria transmission intensity. However, the effect of IPTp-SP has been compromised in 
some areas due to parasite resistance, raising the importance of parasitological and chemoprophylactic surveillance, 
and monitoring SP-resistance markers in the Plasmodium falciparum population.
Methods: Between November 2013 and April 2014 in Nchelenge, Zambia, 1086 pregnant women received IPTp-SP 
at antenatal-care bookings. Blood samples were collected on day 0, and on day 28 post-treatment to test for malaria 
parasites and to estimate SP parasitological efficacy in the treatment and prevention of parasitaemia. A random sam-
ple of 96, day 0 malaria-positive samples were analysed to estimate the prevalence of SP-resistance markers in the P. 
falciparum population.
Results: The overall parasitological and prophylactic failure among women who had paired day 0 and day 28 blood 
slides was 18.6% (95% CI 15.5, 21.8; 109 of 590). Among pregnant women who had asymptomatic parasitaemia on 
day 0, the day 28 PCR-uncorrected parasitological failure was 30.0% (95% CI 23.7, 36.2; 62 of 207) and the day 28 
PCR-corrected parasitological failure was 15.6% (95% CI: 10.6, 20.6; 32 of 205). Among women who tested negative at 
day 0, 12.3% (95% CI: 9.0, 15.6; 47 of 383) developed parasitaemia at day 28. Among the 96 malaria-positive samples 
assayed from day 0, 70.8% (95% CI: 60.8, 79.2) contained the DHPS double (Gly-437 + Glu-540) mutation and 92.7% 
(95% CI: 85.3, 96.5) had the DHFR triple (Asn-108 + Ile-51 + Arg-59) mutation. The quintuple mutation (DHFR tri-
ple + DHPS double) and the sextuple mutant (DHFR triple + DHPS double + Arg-581) were found among 68.8% (95% 
CI: 58.6, 77.3) and 9.4% (95% CI: 4.2, 16.0) of samples, respectively.
Conclusion: The parasitological and chemoprophylactic failure of SP, and the prevalence of resistance markers 
in Nchelenge is alarmingly high. Alternative therapies are urgently needed to safeguard pregnant women against 
malarial infection.
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Background
Pregnant women in malaria-endemic areas are at high 
risk of Plasmodium falciparum infection and related con-
sequences that include stillbirth [1, 2], small for gesta-
tional age [3, 4], preterm birth [4, 5], and low birthweight 
[4, 6]. Preterm birth and low birthweight are associated 
with marked increase in neonatal death [7–10]. The 
World Health Organization (WHO) recommends pro-
viding intermittent preventive treatment in pregnancy 
(IPTp) with sulfadoxine-pyrimethamine (SP) during 
antenatal care (ANC) contacts from the 13th gestational 
week until delivery at no < 4-week intervals in areas of 
moderate to high transmission intensity [11]. IPTp-SP is 
designed to improve birth outcomes by clearing parasi-
taemia at the time of dosing, and to prevent the effects of 
malarial infections acquired between antenatal contacts. 
However, the effectiveness of IPTp-SP has been under-
mined by malaria parasite resistance to SP [12, 13]. The 
WHO malaria treatment guidelines for the management 
of uncomplicated malaria state that countries should 
conduct routine surveillance of treatment efficacy and 
change the first-line therapy when parasite clearance 
rates decrease beneath 90% [14]. Even though IPTp-SP is 
given to asymptomatic pregnant women for the purposes 
of preventing the consequences of malarial infection dur-
ing pregnancy, rather than for the treatment of sympto-
matic and uncomplicated malaria, surveillance is needed 
to determine when and where alternative therapies and 
interventions may be required. This study quantified the 
therapeutic and chemoprophylactic efficacy of IPTp-
SP and the proportion of malaria parasites containing 
mutations in the dihydropteroate synthase (DHPS) and 
dihydrofolate reductase (DHFR) genes associated with 
resistance to SP [15–21].
This observational cohort study was conducted in 
Nchelenge, a rural northern district in the Luapula Prov-
ince with a population of 173,680 [22]. The objectives of 
the study were to estimate: (1) the in vivo parasite-clear-
ance efficacy and prophylactic effects of SP in pregnant 
women during a 28-day period and, (2) the prevalence of 
DHFR and DHPS mutations associated with SP resist-
ance in the same population. Nchelenge has a tropical cli-
mate and rainy season from November to April, followed 
by a dry season between May and October. Despite the 
seasonality of precipitation, malaria transmission occurs 
year-round due to the district’s proximity to Lake Mweru 
and surrounding wetlands.
Methods
Details of enrolment procedures including inclusion 
and exclusion criteria have been previously reported 
[23]. Briefly, 1086 consenting women of all ages and 
gestational-ages < 32 weeks were enrolled consecutively 
at ANC booking if they provided consent, self-reported 
not having taken anti-malarial and/or antibacterial 
drugs in the previous month, and were willing to have 
their HIV test results from routine testing recorded 
by study staff. Participants provided peripheral blood 
samples by finger prick at enrolment (day 0) for prepa-
ration of two blood smears and four blood spots on cir-
cles of  Whatman® filter paper. Thick smear-slides and 
dried blood spots were, respectively used to diagnose 
malaria by microscopy and polymerase chain reaction 
(PCR). Participants received directly observed IPTp-
SP during the same consultation. The follow up visit 
was conducted on day 28 post-treatment during which 
peripheral blood was collected for malaria diagnosis by 
microscopy and PCR. Participants verbally confirmed 
having not taken any anti-malarial treatment between 
day 0 and day 28.
In alignment with the WHO treatment efficacy proto-
col [24], sample size was determined using classical sta-
tistical methods. It was assumed that the proportion of 
parasitological failures in the study population was 10%. 
To detect 10% parasitological failure with 95% confidence 
level and 5% precision, a sample size of 138 asympto-
matic pregnant women was required. Only women who 
were eligible to receive IPTp-SP were included. Study 
staff visited the homes of participants on day 28 if they 
did not present at the facility. Participants who developed 
symptoms of malarial infection before day 28 were tested 
and, if positive, were given rescue treatment by the health 
centre staff in accordance with national guidelines.
Malaria microscopy, DNA extraction and PCR amplification
Laboratory staff stained thick blood films using 10% 
Giemsa which were then read by two independent 
microscopists. Details of slide-reading methods have 
been reported elsewhere [23]. Parasite DNA extrac-
tion from dried blood spots was carried out using the 
Chelex method as presented previously [25]. The detec-
tion of P. falciparum was conducted using a nested-
PCR method as described by Snounou et  al. [26] with 
modifications to the PCR parameters [27].
Keywords: Intermittent preventive treatment of malaria in pregnancy (IPTp), Sulfadoxine-pyrimethamine (SP), DHPS 
double mutation (gly-437 + glu-540), DHFR triple mutation (asn-108 + ile-51 + arg-59), Quintuple mutation (DHFR 
triple + DHPS double), Sextuple mutation (DHFR triple + DHPS double + arg-581)
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Detection of SP resistance markers
A sample size of 96 was needed to detect a 50% preva-
lence of quintuple mutation among pregnant women 
with 95% CIs ± 10%. Parasite DNA template extracted 
for malaria detection by PCR was used for this part of 
the study. Nested PCR and restriction enzyme digestion 
methods were both used to detect antifolate drug resist-
ance polymorphisms in the DHFR and DHPS genes [28]. 
Briefly, all PCR reactions were carried out in total vol-
umes of 25 µl using Thermo  Scientific® Dream Taq PCR 
Master Mix (2X) and 0.5 µM of each primer and 2 µl of 
template. A 2 µl of the primary amplicon was used as a 
template in the secondary reaction. Negative and positive 
controls were included in every batch of sample process-
ing, from extraction to amplification, and finally electro-
phoresis. Secondary PCR amplicons were analysed by gel 
electrophoresis to confirm amplification and band inten-
sity before enzyme digestion. Restriction-digest assays 
were set up following manufacturer instructions; 4 µl of 
amplicon was used as substrate in the reaction mix. For 
samples showing faint bands in the nested PCR product, 
6–8  µl was used as substrate. Amplicon and restriction 
fragments were analysed on ethidium bromide 2% aga-
rose gels and visualized under ultraviolet transillumi-
nation on a Biosens (Genescope V1.76) digital imaging 
system.
Determination of in vivo parasite‑clearance efficacy 
and prophylactic effect of SP
In vivo parasite-clearance efficacy and prophylactic effect 
of SP was established based on malaria microscopy [24] 
and merozoite surface protein-2 (MSP2) genotyping [29, 
30] which differentiated cases of recrudescence from 
reinfection. The two blood smears collected at enrol-
ment on day 0 and day 28 post-treatment were used to 
estimate the in vivo parasite-clearance efficacy and pro-
phylactic effect. Women were classified as having parasi-
tological-clearance failures if they had a malaria-positive 
blood smear both at day 0 and day 28, and genotyping of 
MSP2 confirmed recrudescence and ruled out new infec-
tions [29, 30]. Women who had a negative blood slide at 
day 0 and became slide-positive at day 28 and those who 
were positive at day 0 and had new infections by day 28 
defined by MSP2 genotyping, were classified as prophy-
lactic failures.
Polymorphic regions of MSP2 were amplified by nested 
PCR. Primary PCR primers corresponding to the con-
served sequence flanking this region [31] were used, 
whereas the secondary PCR primers were used to amplify 
the IC3D7 and FC27 allelic families of MSP2 [32]. For 
controls, DNA from HB3 and 3D7 laboratory strains 
were used. Briefly, all PCR reactions were carried out in 
total volumes of 25  µl using Thermo  Scientific® Dream 
Taq PCR Master Mix (2X) and 0.5 µM of each primer and 
2 µl of template. A 2 µl of the primary amplicon was used 
as a template in the secondary reaction.
The secondary amplicon from each sample was then 
analysed using electrophoresis on 2% ethidium bromide 
stained agarose gels. Samples from individual partici-
pants were loaded in adjacent lanes. In cases where there 
was no amplification, PCR was repeated using five-times 
the quantity of template DNA. In cases where no ampli-
con was detected after the second reaction, amplifica-
tion was classified unsuccessful [33]. Two independent 
laboratory personnel compared band sizes manually; any 
discordant classification was settled by a third labora-
tory staff member. Reinfection and recrudescence were 
defined as described elsewhere [33]. Briefly, reinfec-
tion was defined as having completely different alleles 
between parasites from day 0 and from day 28; recrudes-
cent infection was assigned if the same allele was found 
between parasites at day 0 and day 28.
Statistical analysis
Data were double-entered in EpiData version 3.1 soft-
ware [34], cleaned, processed and analysed using Stata 
software version 13 [35]. This involved visual checks for 
consistency and validity, as well as variable frequencies 
to check for missing data. Variables were then recoded 
and composite variables generated for the DHFR triple 
(Ile-51 + Arg-59 + Asn-108), DHPS double mutant (Gly-
437 + Glu-540), quintuple (DHFR triple + DHPS double) 
and sextuple (quintuple + Gly-581) mutants.
Parasitological failure was defined as presence of para-
sites on day 0 and day 28 post treatment that was deemed 
to be recrudescence and not a new infection. Prophylac-
tic failure was defined as the presence of parasitaemia in 
previously aparasitaemic women on day 28 post-treat-
ment, as well as parasitaemia deemed to be a new-infec-
tions in women who tested positive at day 0 and day 
28. Overall parasitological and prophylactic failure was 
defined as the inability of SP to clear existing parasites 
and to prevent infection within 28 days of administration.
Baseline characteristics among asymptomatic parasi-
taemic women were compared between paucigravidae 
(primi- and secundigravidae combined) and multigravi-
dae using appropriate tests, namely Chi-squared test for 
proportions, t-tests for means and Mann Whitney for 
medians. Prevalence estimates of the DHFR triple, DHPS 
double; DHFR + DHPS quintuple and sextuple mutants 
and their 95% CIs were then calculated.
Parasitological and prophylactic failure in paucigravi-
dae and multigravidae women was compared using 
Chi-squared test, while the median age of women who 
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experienced failure compared to those who did not was 
assessed with the Mann Whitney test.
Results
A total of 1086 ANC attendees were enrolled from 
November 2013 to April 2014. Among them, 343 women 
had asymptomatic parasitaemia at day 0 (Fig. 1). Of these, 
56.3% (n = 193) and 43.7% (n = 150) were paucigravidae 
and multigravidae, respectively. The median age of pauci-
gravidae was significantly lower than that of multigravi-
dae, 18.4 versus 27.3 years, P < 0.001. Use of bed nets on 
the previous night was significantly higher among mul-
tigravidae than paucigravidae, respectively, 42.7% versus 
27.5%, P = 0.003. Parasite count measured by geometric 
mean was lower in multigravidae compared to pauci-
gravidae, 849 versus 1310, P = 0.001. Other characteris-
tics of asymptomatic parasitaemic women in this cohort 
stratified by gravidity are shown in Table 1.
Of the women who attended the day 28 visit among 
those who received IPTp-SP at day 0 and were eligible 
to attend the day 28 visit, 37.6% (356 of 946) were lost to 
follow-up. The proportions of socio-demographic fac-
tors such as age, gravidity and marital status, did not dif-
fer between the lost to follow-up group and those who 
were retained with the exception of the number of years 
of schooling. Among women who were lost to follow-
up, 54.4% reported spending 7 years and above in school 
versus 65.5% among those who were retained at day 28, 
P < 0.001.
Submicroscopic malaria infection
The prevalence of malaria detected by polymerase chain 
reaction and microscopy have been reported elsewhere 
and were 57.8% (621 of 1074) and 31.8% (343 of 1079), 
respectively. The prevalence of submicroscopic malaria 
infection (microscopy negative but PCR positive) was 
38.9% (285 of 731).
Parasitological‑clearance efficacy of IPTp‑SP over a 28‑day 
period
Among women who tested positive for malaria on day 0 
measured by microscopy, 60.3% (207 of 343) were tested 
again at day 28 post-treatment. Sulfadoxine-pyrimeth-
amine cleared parasitaemia present on day 0 in 70.0% 
(145 of 207) of pregnant women confirmed by day 28 test 
(Table  2). Among the 62 women who had parasitaemia 
on both day 0 and day 28, MSP-2 genotyping was unsuc-
cessful in 2 women, 32 were classified as recrudescent 
infections and 28 were re-infections. Thus, the day 28 
PCR-corrected parasitological failure was 15.6% (95% CI: 
11.2, 21.3; 32 of 205).
Among women with a negative malaria smear at day 0, 
52.0% (383 of 736) were also screened at day 28. Of these 
women, 12.3% (47 of 383) became malaria parasite posi-
tive at day 28 post-treatment (Table 2). In addition, of the 
62 women who had malaria parasitaemia at day 0 and day 
28 post treatment, 28 were categorized as reinfections. 
Thus, the total prophylactic failure was 18.3% (95% CI: 
14.8, 22.3; 75 of 411). Overall parasitological and prophy-
lactic failure by day 28 post IPTp-SP administration was 
18.6% (95% CI: 15.5, 21.8; 109 of 590) (Table 2).
The proportion of parasitological failure observed 
among paucigravidae was much higher than that 
observed among multigravidae, 22.4% (26 of 116) ver-
sus 6.7% (6 of 89), P = 0.002. Similarly, the proportion 
of prophylactic failure was higher among paucigravidae, 
28.4% (38 of 134) than multigravidae13.4% (37 of 277), 
P < 0.001. Younger women were more likely to experience 
parasitological failure. The median age of women who 
experienced parasitological failure was 19  years (IQR, 
17.5, 21.5) compared to 22 years among those whose par-
asitaemia cleared (IQR, 19, 28), P < 0.001. The median age 
of women who experienced prophylactic failure was 24 
(IQR, 20–29) years while that of women who maintained 
their malaria negative status was 26 (IQR, 22–32) years, 
P = 0.027.
Prevalence of DHFR and DHPS mutations associated 
with SP resistance
There was near saturation of the pyrimethamine-resistant 
DHFR Asn-108 mutation at 94.8% (91 of 96) among the 
P. falciparum positive samples. Mixed infection of Asn-
108 occurring with the wild type Ser-108 was observed 
in 3.1% (3 of 96) of samples. High levels of the DHFR Ile-
51 and Arg-59 mutants as shown in Fig. 2 as well as the 
DHPS Gly-437 and Glu-540 in Fig. 3. Table 3 contains the 
prevalence of the double, triple, quintuple and sextuple 
mutants. Proportions of specific mutants were found as 
follows: 70.8% (68 of 96) had the DHPS double mutant 
(Gly-437 + Glu-540); 92.7% (89 of 96) had the DHFR tri-
ple mutant (Asn-108 + Ile-51 + Arg-59); 68.8% (66 of 96) 
had the quintuple mutant (DHFR triple + DHPS double). 
The mutation most associated with SP treatment failure 
in East Africa, the sextuple mutant (DHFR triple + DHPS 
double + Arg-581), was observed in 9.4% (9 of 96) of sam-
ples with 2 of these occurring as mixed infections with 
the wild type. Table 4 summarizes the number of samples 
that carried a particular combination of point mutations 
associated with SP resistance.
Discussion
Overall, almost one-fifth (18.6%) of pregnant women 
in the study experienced a parasitological and prophy-
lactic failure of SP at day 28 post-IPTp treatment in an 
area where 68.8% of malaria parasites carried the quin-
tuple mutant and 9.4% expressed the sextuple mutant. 
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Fig. 1 Enrolment flow diagram for in vivo efficacy and prophylactic effect analyses of sulphadoxine-pyrimethamine given to pregnant women as 
IPTp in Nchelenge District, Zambia
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Table 1 Baseline characteristics
Asymptomatic pregnant women of Nchelenge District, Zambia, enrolled in a modified in vivo efficacy study of sulphadoxine-pyrimethamine stratified by gravidity
SD = standard deviation
*P-value comparing paucigravidae and multigravidae, Chi-squared for proportions, t-test for means, Mann–Whitney for medians
Characteristic Total (N = 343) Paucigravidae (N = 193) Multigravidae (N = 150) P‑value*
Age, median (interquartile range) 22 (19–28) 19 (18–21) 28 (25–32) < 0.001
Age ≤ 20 years, % 43.7% 70% 10% < 0.001
Used a bed net last night, % 34.1% 27.5% 42.7% 0.003
Maternal weight in kilograms, mean (SD) 52.6 (8.7) 50.8 (7.0) 55.0 (10.0) < 0.001
Education in years, mean (SD) 7.6 (7.6) 8.2(7.1) 6.8 (8.2) 0.079
Gestational age in weeks at enrolment, mean (SD) 21.6 (4.6) 20.9 (4.3) 22.6 (4.6) 0.001
Parasite density, geometric mean (95% CI) 1082 (962–1217) 1310 (1120–1532) 849 (713–1010) 0.001
Table 2 Estimates of  treatment and  prophylactic failure of  sulphadoxine-pyrimethamine among  antenatal care 
attendees in Nchelenge District, Zambia
PCR polymerase chain reaction diagnostic methods
a All positives among women who took SP at enrolment and tested malaria positive at day 28 which includes prophylactic and parasitological failures
b The total includes aparasitaemic at day 0 and parasitaemic at day 28 plus the 28 women who were parasitaemic at day 0 and day 28 due to reinfection
c Two samples could not be differentiated between recrudescence or reinfection, which is reflected in the smaller denominator (205) of samples after PCR correction 
for parasitological failure





Overall parasitological and prophylactic  failurea 590 18.6 (109) 15.5, 21.8
Total prophylactic  failureb 411 18.3 (75) 14.8, 22.3
Day 0 malaria positives
 Day 28 PCR uncorrected parasitological failure 207 30.0 (62) 23.7, 36.2
 Day 28 PCR corrected parasitological failure 205c 15.6 (32) 11.2, 21.3
 Day 28 PCR corrected reinfection 60 46.7 (28) 34.2, 59.6
Day 0 malaria negatives
 Day 28 PCR uncorrected prophylactic failure 383 12.3 (47) 9.0, 15.6
Fig. 2 Prevalence of Plasmodium falciparum DHFR mutations in pregnant women of Nchelenge District, Zambia
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Sulfadoxine-pyrimethamine retained partial efficacy 
in parasite clearance among pregnant women who had 
asymptomatic malarial infections. Similar observations 
have been made elsewhere despite a moderate to high 
prevalence of the quintuple mutant and presence of the 
sextuple mutant [36, 37].
The risk of parasitological failure was higher among 
paucigravidae than multigravidae. This may be partially 
attributable to primigravidae and secundigravidae hav-
ing acquired less semi-immunity to malarial infection 
in pregnancy than multigravidae [3, 38, 39] and, there-
fore, relying more on drug-action to clear parasites. 
There was a difference, as well, among gravidae and use 
of insecticide-treated bed nets where a higher propor-
tion was observed among multigravidae compared to 
paucigravidae.
It is difficult to establish the precise prophylactic fail-
ure rate because it is unknown how many women who 
tested negative by microscopy at day 0 may have later 
been exposed to malarial infection post-treatment. This 
Fig. 3 Prevalence of Plasmodium falciparum DHPS point mutations in pregnant women of Nchelenge District, Zambia
Table 3 Plasmodium falciparum antifolate multiple 
mutants among  96 malaria-positive pregnant women 
at antenatal care booking in Nchelenge District, Zambia






DHFR triple 92.7 (89) 85.3, 96.5
DHPS double 70.8 (68) 60.8, 79.2
DHFR/DHPS quintuple 68.8 (66) 58.6, 77.3
DHFR/DHPS sextuple 9.4 (9) 4.2, 16.0
Table 4 Results of DHFR and DHPS genotyping of Plasmodium falciparum samples from 96 pregnant women at antenatal 
care booking in Nchelenge District, Zambia
− = wild type
+  = Mutant or mixed genotype
Number of samples dhfr51 dhfr59 dhfr108 dhps437 dhps540 dhps581
1 − − − − − −
2 + − + − − −
2 + + + − + −
1 + − + + + −
1 + + − + + −
7 + + + − − −
16 + + + + − −
57 + + + + + −
9 + + + + + + 
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is because some women may have become infected after 
receiving IPTp-SP, cleared the parasitaemia to reflect 
important prophylactic effect but were indistinguish-
able from other women who may have never have been 
exposed to the parasite. Nonetheless, calculating the pro-
phylactic failure based on the number of malaria posi-
tive women from those who tested negative at day 0 is a 
reasonable and common proxy for the estimate of true 
prophylactic failure, especially in areas with moderate to 
high malaria transmission like this study area [40].
Only MSP-2 genotyping was conducted to distinguish 
recrudescence from reinfection in the current study. 
Although genotyping for genes MSP-1, MSP-2 and 
GLURP was not done in this study, MSP-2 results alone 
are reliable since the gene is known to provide a more 
accurate measure of treatment outcomes compared to 
MSP-1 and GLURP [33].
Point mutations associated with SP resistance were 
very common in this study. The prevalence of both the 
quintuple and the sextuple mutants among pregnant 
women was moderate but higher than recorded in earlier 
studies, both of which were conducted in the same prov-
ince, Luapula [37]. The first of these prior studies docu-
mented the sextuple mutant among pregnant women at 
two health centres in Mansa District, 250 kms from the 
Nchelenge District between January 2010 and May 2011. 
The prevalence of the quintuple and sextuple mutation 
was 63.0% and 2.0%, respectively [37]. The second study 
carried out between February and April of 2013 among 
pregnant women in the Nchelenge District reported 
the prevalence of the quintuple and sextuple mutant to 
be 17.0% and 3.0%, respectively [41]. The current find-
ings suggest the quintuple mutation is as common in 
Nchelenge as it is Mansa with the sextuple mutant on the 
rise in Nchelenge. This is cause for concern. The addi-
tion of the 581G to form the sextuple mutation renders 
malaria parasites ‘super resistant’ to SP and is strongly 
associated with treatment failure among cases of uncom-
plicated malarial infection [42]. Nchelenge appears to 
be on a related threshold based on a meta-analysis that 
found 2 or more doses of IPTp-SP no longer protected 
against the incidence of low birthweight among multi-
gravidae where the prevalence of 581G was > 10.1% [43].
Only four studies conducted in Zambia have esti-
mated the prevalence of SP resistance markers, two in 
the general population [44, 45] and two in pregnant 
women [37, 41]. Monitoring the prevalence of SP-resist-
ance markers and the in vivo efficacy of SP in Zambia is 
critically important, especially in areas of high malaria 
transmission. Although IPTp-SP is not given to patients 
with uncomplicated malaria, surveillance is critically 
important for guiding policymakers around decisions 
related to when and where alternative therapies and 
interventions might be required. However, part of the 
challenge with IPTp and resistance monitoring is that 
there are no clear second-line therapies to promote. 
The leading candidate to replace SP is dihydroarte-
misinin-piperaquine (DP) which is superior to SP in 
terms of reducing malarial infections among pregnant 
women. However, a recent meta-analysis of pooled data 
from three IPTp trials suggests that DP is not superior 
to SP in terms of reducing the incidence of low birth-
weight [46]. Moreover, a mediation analysis using the 
same trial data showed that protection conferred by SP 
against low birthweight is actually derived more from 
its non-malarial properties than its anti-malarial effects 
[46]. Consequently, to achieve superiority, DP needs 
to have a partner compound that confers non-malarial 
protection against low birthweight. Alternatively, SP 
could be combined with a potent anti-malarial therapy, 
perhaps even DP, to improve its anti-malarial protec-
tion while maintaining its non-malarial effects against 
low birthweight. Clinical trials are urgently needed to 
identify a clear path forward.
The prevalence of submicroscopic malaria infection 
among pregnant women in the current study was consid-
erable. Other studies have found wide spread submicro-
scopic malaria infections [47–49]. Many asymptomatic 
infections are submicroscopic and can only be detected 
by molecular methods. Achieving malaria elimination 
requires targeting the human reservoir of infection, 
including those with asymptomatic infection [50].
The limitations in this study include the fact that sam-
ples were only collected at day 0 and day 28. These col-
lection time points do not allow for determining early 
parasitological failure. Secondly, samples were not col-
lected from the six women who verbally indicated that 
they had taken anti-malarial drugs before day 28, there-
fore requiring their exclusion from treatment-failure 
analysis at day 28. Another limitation is the fact that 
some of the women who tested negative on day 0 could 
have had submicroscopic infections which became posi-
tive by day 28 which may have affected the estimate of 
prophylactic failure.
The number of women who were lost to follow-up was 
large. However, baseline characteristics did not differ 
between women lost to follow-up and those who were 
followed to day 28, with one exception: the number of 
years of schooling. This could have affected the results 
in terms of proportions of parasite clearance and parasi-
tological failure if women lost to follow-up are different 
from those who were retained at day 28. However, given 
that these women are residents of the same geographic 
area where high malaria endemicity affects the com-
munity broadly [40], it is difficult to know whether this 
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difference in years of schooling would have changed this 
observations.
Conclusions
The quintuple and sextuple mutants were observed 
in this study population. Sulfadoxine-pyrimethamine 
retains partial efficacy in clearing parasites in pregnant 
women with moderate prevalence of the highly resist-
ant quintuple mutation. These results suggest that con-
tinued monitoring is essential for future policy-making 
and there is a clear need to identify alternative regi-
mens for use in IPTp.
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